Mushroom Lion’s Mane / P53 Cancer Research Results

mushLions, Mushroom Lion’s Mane: Click to Expand ⟱
Features:

Lion’s Mane mushroom (Hericium erinaceus; “HE”; culinary + medicinal mushroom). Key bioactives include erinacines (notably erinacine A; typically mycelium-derived) and hericenones (often fruiting-body-associated), plus polysaccharides (β-glucans).

Primary mechanisms (conceptual rank):
1) ↑ Neurotrophic signaling (NGF/BDNF-related; CREB/neurite outgrowth)
2) ↓ Neuroinflammation (e.g., NF-κB/cytokine tone; microglial activation models)
3) ↑ Antioxidant/stress-defense (often ↑ NRF2; ↓ ROS burden; mitochondrial protection)

Bioavailability / PK relevance: activity depends strongly on extract type (mycelium vs fruiting body; erinacine-standardized vs not). Some erinacines are reported to be BBB-permeable in the literature; human PK is not well-characterized for most commercial products.

In-vitro vs oral exposure: many anti-cancer / signaling findings use extract concentrations likely above achievable systemic levels from typical supplements (qualifier: high concentration only unless otherwise demonstrated in vivo).

Clinical evidence status: small human trials/pilot RCTs for cognition/early AD/MCI and healthy adults (signals but limited); cancer evidence remains largely preclinical/adjunct-hypothesis.

Lion’s Mane Mushroom (Hericium erinaceus) is renowned for its potential health benefits, particularly in areas like neuroprotection, cognitive function, and immune support.

-Most commonly cited mechanisms of Lion’s Mane is its ability to stimulate the synthesis of Nerve Growth Factor (NGF)
-Specific compounds such as hericenones and erinacines present in the mushroom are thought to be responsible for this effect.
-May inhibit NF-κB Pathway
-May lower the production of pro-inflammatory cytokines (e.g., TNF-α, IL-6)
-Neutralize free radicals, reducing oxidative stress
-Lion’s Mane influences gut health and, in turn, the gut-brain axis
-Anti-inflammatory responses, antioxidant protection

-Mushrooms, including Lion’s Mane (Hericium erinaceus), contain ergosterol—a precursor to vitamin D. When exposed to ultraviolet (UV) light (such as sunlight), ergosterol is converted to vitamin D₂ (ergocalciferol).

Lion’s Mane (Hericium erinaceus) — Cancer vs Normal Cell Pathway Map

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 PI3K/AKT survival signaling ↓ ↔ (context-dependent) R/G Pro-apoptotic shift; reduced proliferative signaling Reported suppression of PI3K/AKT in cancer models; often paired with apoptosis readouts (model- & extract-dependent).
2 RAS/MAPK (ERK) proliferative signaling ↓ ↔ (context-dependent) R/G Growth inhibition / reduced mitogenic drive Observed in some cancer cell studies alongside reduced viability; dose/time dependence common.
3 Intrinsic apoptosis (mitochondrial; caspases) ↑ ↔ / ↑ (cytoprotection; model-dependent) R/G Cancer cell death / chemosensitization hypothesis Frequently reported outcome in vitro; translation depends on achievable exposure and tumor selectivity.
4 NF-κB / inflammatory cytokine programs ↓ (context-dependent) ↓ R/G Anti-inflammatory / anti-survival signaling Anti-inflammatory effects are central in neuro models; in tumors may reduce pro-survival inflammation but can be tumor-type specific.
5 ROS / redox stress balance ↑ or ↓ (dose-dependent) ↓ P/R Redox modulation (pro-oxidant cytotoxicity vs antioxidant protection) Normal cells: commonly described as antioxidant/mitochondrial-protective. Cancer cells: extracts can act cytotoxically at higher concentrations (biphasic behavior).
6 NRF2 axis (stress-defense / resistance) ↔ / ↑ (context-dependent) ↑ R/G Stress-response activation Normal cells: ↑ NRF2 generally cytoprotective. Cancer: ↑ NRF2 can be double-edged (possible therapy resistance in some contexts).
7 Cell cycle control (checkpoint enforcement) ↓ proliferation ↔ G Cell-cycle arrest phenotype Common downstream phenotype in preclinical cancer studies; specifics vary by line/extract.
8 Migration / invasion (EMT, MMP-related) ↓ (model-dependent) ↔ G Anti-metastatic phenotype hypothesis Reported in some preclinical literature; often requires sustained exposure.
9 Angiogenesis programs (e.g., VEGF/HIF-1α coupling) ↓ (model-dependent) ↔ G Anti-angiogenic hypothesis Evidence is less consistent; often indirect via inflammation/redox signaling.
10 Ca²⁺ handling / ER–mitochondria stress coupling ↔ (model-dependent) ↔ (model-dependent) P/R Stress signaling modulation Not a universal primary axis; consider when apoptosis/UPR/mitochondrial stress is a defined readout in a given model.
11 Ferroptosis (iron/lipid peroxidation) ↔ (insufficiently established) ↔ R/G Not a dominant canonical mechanism May become relevant only in specific redox/iron contexts; not consistently central in HE literature.
12 Clinical Translation Constraint ↓ (constraint) ↓ (constraint) — Exposure + standardization limitations Major constraint: product heterogeneity (mycelium vs fruiting body; erinacine-standardized vs not), limited human PK, and many in-vitro doses likely supra-physiologic.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr


AD relevance: Lion’s Mane (Hericium erinaceus; especially erinacine-A–enriched mycelium preparations) is primarily studied as a neurotrophic + neuroprotective dietary intervention with small human trials/pilot RCTs in early AD/MCI and related cognitive outcomes.

Primary mechanisms (conceptual rank):
1) ↑ Neurotrophic signaling (↑ NGF/BDNF-related pathways; CREB/neurite outgrowth)
2) ↓ Neuroinflammation (↓ NF-κB/cytokines in models; microglial tone)
3) ↑ Stress-defense & mitochondrial resilience (often ↑ NRF2; ↓ ROS burden)

Bioavailability / PK relevance: effects depend on standardized preparations (erinacine A content; dosing regimen). Evidence base includes a ~49-week pilot double-blind placebo-controlled study of erinacine-A–enriched mycelium; overall evidence remains limited by sample sizes and product variability.

Clinical evidence status: small human trials/pilot RCTs (signals but not definitive; adjunct/early evidence).

Lion’s Mane (Hericium erinaceus) — AD/Neurodegeneration Pathway Map

Rank Pathway / Axis Cells TSF Primary Effect Notes / Interpretation
1 Neurotrophins (NGF/BDNF-related; CREB/neuritogenesis) ↑ G Synaptic support / plasticity, neurite outgrowth Core proposed mechanism; often linked to erinacines/hericenones and downstream neurogenesis/survival signaling in models.
2 Neuroinflammation (NF-κB, cytokine tone; microglial activation models) ↓ R/G Reduced inflammatory stress on neurons Anti-inflammatory signaling is commonly invoked as neuroprotective; timing can be acute (signaling) → chronic (phenotype).
3 ROS / oxidative stress burden ↓ P/R Lower oxidative damage pressure Often paired with mitochondrial protection claims; may be secondary to NRF2 activation.
4 NRF2 antioxidant-response program ↑ R/G Stress-defense upshift Generally aligned with neuroprotection; interpret alongside redox context and dosing/extract standardization.
5 Mitochondrial function / bioenergetics resilience ↑ R/G Improved cellular resilience under stress Often described downstream of reduced ROS/inflammation; phenotype-level outcomes require sustained exposure.
6 Aβ / tau-associated pathology (amyloid/tau cascades) ↓ (model-dependent) G Reduced pathological burden (preclinical emphasis) Evidence is stronger preclinically than clinically; treat as supportive/secondary unless specific human biomarker replication exists.
7 Ca²⁺ homeostasis / excitotoxic vulnerability ↔ (context-dependent) P/R Excitotoxic stress modulation (hypothesis) Include when models explicitly measure Ca²⁺/ER stress/UPR; not always primary in HE clinical framing.
8 Clinical Translation Constraint ↓ (constraint) — Evidence + standardization limitations Small trials/pilot RCTs; product heterogeneity (erinacine content; mycelium vs fruiting body) and limited human PK constrain inference.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr
P53, P53-Guardian of the Genome: Click to Expand ⟱
Source: TCGA
Type: Proapototic
TP53 is the most commonly mutated gene in human cancer. TP53 is a gene that encodes for the p53 tumor suppressor protein ; TP73 (Chr.1p36.33) and TP63 (Chr.3q28) genes that encode transcription factors p73 and p63, respectively, are TP53 homologous structures.
p53 is a crucial tumor suppressor protein that plays a significant role in regulating the cell cycle, maintaining genomic stability, and preventing tumor formation. It is often referred to as the "guardian of the genome" due to its role in protecting cells from DNA damage and stress.
TP53 gene, which encodes the p53 protein, is one of the most frequently mutated genes in human cancers.
Overexpression of MDM2, an inhibitor of p53, can lead to decreased p53 activity even in the presence of wild-type p53.
In some cancers, particularly those with mutant p53, there may be an overexpression of the p53 protein.
Cancers with overexpression: Breast, lung, colorectal, overian, head and neck, Esophageal, bladder, pancreatic, and liver.
Scientific Papers found: Click to Expand⟱
3807- mushLions,    Searching for a Longevity Food, We Bump into Hericium erinaceus Primordium Rich in Ergothioneine: The “Longevity Vitamin” Improves Locomotor Performances during Aging
*AntiAge↑, *other↑, *NOS2↓, *COX2↓, *P53↑, *neuroP↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Transcription & Epigenetics ⓘ

other↑, 1,  

DNA Damage & Repair ⓘ

P53↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,  

Clinical Biomarkers ⓘ

NOS2↓, 1,  

Functional Outcomes ⓘ

AntiAge↑, 1,   neuroP↑, 1,  
Total Targets: 6

Scientific Paper Hit Count for: P53, P53-Guardian of the Genome
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:325  Target#:236  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page